Antibiotic-resistant Campylobacter: could efflux pump inhibitors control infection?

Journal of Antimicrobial Chemotherapy Advance Access published November 20, 2006 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkl470 Antibiotic-resistant Campylobacter: could efflux pump inhibitors control infection? Teresa Quinn 1, Jean-Michel Bolla 2, Jean-Marie Pagès 2 and Séamus Fanning 1 * Introduction 1 Centre for Food Safety, School of Agriculture, Food Science and Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland; 2 EA 2197, IFR 48, Faculté de Médecine, Université de la Méditerranée, 27 Boulevard Jean Moulin 13385, Marseille Cedex 05, France Campylobacter is the most common cause of bacterial gastroenteritis in the world. Poultry is the main reservoir of human infections. The widespread use of antibiotics in agriculture and veterinary medicine has resulted in the emergence of an increasing number of antibiotic-resistant Campylobacter strains that can be transmitted to humans through the food chain. Of particular concern to public health is the prevalence of resistance to macrolides and fluoroquinolones that are used in the treatment of life-threatening campylobacteriosis. The CmeABC efflux system has been shown to contribute to the intrinsic and acquired resistance to these antibiotics. In addition, by mediating resistance to bile, it is essential for colonization of the chicken gut in vivo. Inhibition of CmeABC may provide an effective means of reversing antibiotic resistance and decreasing the transmission of Campylobacter via the food chain. This would positively impact on public health by decreasing the morbidity, mortality and increased healthcare costs associated with the treatment of antibiotic-resistant Campylobacter. Keywords: fluoroquinolones, macrolides, colonization, resistance to bile, campylobacteriosis Since it was first isolated from faeces in the 1970s Campylobacter has risen from near obscurity to currently being heralded as one of the major causative agents of bacterial gastroenteritis in humans worldwide. 1,2 Greater than 90% of cases of Campylobacter gastroenteritis are caused by Campylobacter jejuni, with Campylobacter coli being responsible for most of the remaining infections. 3 Campylobacter is a zoonotic pathogen that colonizes a variety of wild and domestic animals. Commercial poultry are considered the main reservoir of human Campylobacter infections even though other risk factors for infection such as raw milk, water and the direct zoonotic transmission from contact with infected pets have been identified. 2,4,5 Since most sporadic cases of human campylobacteriosis have been associated with the consumption of, 6,7 or contact with raw or undercooked poultry, 8 reduction of pathogens at relevant points of the farm to fork continuum could potentially reduce the risks to human health. Unfortunately, the heavy bacterial burden in poultry flocks makes it virtually impossible to control Campylobacter during poultry processing. 9 Consequently, user-friendly and consumer acceptable intervention strategies are currently being sought that will reduce colonization of poultry with Campylobacter. 10 12 Although most cases of Campylobacter enteritis are selflimiting and require only supportive therapy such as maintenance of hydration and electrolyte balance, antibiotic therapy is warranted in immunocompromised individuals or in cases of persistent enteritis or extraintestinal infection. 2 Under these circumstances, macrolides or fluoroquinolones are the antibiotics of choice. 1,2 The prevalence of macrolide and fluoroquinolone resistance in Campylobacter raises a concern for human health as it could compromise treatment. Indeed, infection with antibioticresistant Campylobacter is associated with longer duration of illness, increased risk of death and invasive disease and escalating healthcare costs. 13 17 Multiple mechanisms for antibiotic resistance exist in Campylobacter. 18 Efflux was first postulated as a mechanism of multidrug resistance in Campylobacter in 1995. 19 In 2002, a chromosomally encoded multidrug resistance-nodulation-cell division (RND) efflux system CmeABC, was identified and characterized in C. jejuni, 20,21 and later in C. coli. 22 It is constitutively expressed in wild-type Campylobacter strains and extrudes a broad range of antibiotics, dyes, bile salts and detergents. 20 Although the genetic mechanisms for fluoroquinolone and macrolide resistance have largely been attributed to target gene mutations in the quinolone resistance determining... *Corresponding author. Tel: +353-1-716-6082; Fax: +353-1-716-6091; E-mail: sfanning@ucd.ie... Page 1 of 7 Ó The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

region of the gyra 23 and in domain V of the 23S rrna, 23,24 there is considerable evidence that the CmeABC efflux pump contributes to the intrinsic and acquired resistance to these antibiotics. 20,21,25 29 In addition to its role in antibiotic resistance, by mediating resistance to bile in the intestinal tract CmeABC has been reported to be essential for the in vivo colonization of chickens by Campylobacter. 30 Here we review current trends in resistance to clinically relevant antibiotics in Campylobacter and the contribution of efflux pumps to antibiotic resistance, in particular to fluoroquinolones and macrolides. The potential for the use of efflux pump inhibitors as therapeutic agents for the treatment of human campylobacteriosis and for the prevention of colonization in animal reservoirs is discussed. Antibiotic resistance in Campylobacter trends and driving forces Antibiotic resistance in both medicine and agriculture has become a major public health concern in recent years. As Campylobacter may be transferred from animals to humans, the development of antibiotic resistance among Campylobacter spp., arising from the use of antibiotics in food animals as therapeutic agents or growth promoters, is a matter of concern. 31 Increasing numbers of resistant C. jejuni strains makes the clinical management of infection more difficult by prolonging illness and compromising the treatment of cases of bacteraemia. 32 Of particular concern in Campylobacter is resistance to fluoroquinolones and macrolides, which are the antibiotics of choice for the treatment of gastroenteritis. Susceptibility data indicate that ciprofloxacin resistance is emerging at a rapid pace. 2,17,33 Rates of fluoroquinolone resistance in Taiwan, Thailand and Spain as high as 90% have been reported, 34 36 limiting the usefulness of fluoroquinolones in the treatment of community-acquired diarrhoea in these regions. Although lower frequencies of up to 45% have been reported in other countries, current trends show that resistance is increasing. 33,37 40 Emergence of fluoroquinolone resistance coincided with the introduction of fluoroquinolones in veterinary medicine. 14,41 It has been postulated that the increase in the numbers of fluoroquinolone-resistant Campylobacter isolated from human infections results from the emergence of resistant strains in poultry as a result of fluoroquinolone use. 14,41,42 Support for this comes from the findings of Smith et al. 14 who showed that the strain types were similar in domestically acquired human infections and local poultry flocks in Minnesota. Furthermore, fluoroquinolone treatment of Campylobacter-colonized broiler chickens has been reported to induce resistance under experimental conditions. 43 The strongest evidence to support the connection between Campylobacter infections in humans and fluoroquinolone use in poultry production systems comes from a study of human campylobacteriosis in Australia where fluoroquinolones are prohibited for use in poultry production. Despite regular use of fluoroquinolones in medicine in Australia there are few confirmed cases of domestically acquired fluoroquinoloneresistant campylobacteriosis. 44 Poultry producers in some countries have elected to voluntarily ban the use of fluoroquinolone drugs in commercial flocks. However, fluoroquinolone resistance has persisted even in the absence of selective pressure. 45 The rapid emergence of fluoroquinolone-resistant isolates may be attributable at least in part to an enhanced fitness. 46 When fluoroquinolone-resistant and -susceptible isolates are co-inoculated the former out-compete the latter, indicating that these isolates may be biologically fitter, conferring a selective advantage. Since the 1990s, a significant increase in the prevalence of resistance to macrolides amongst human Campylobacter isolates has been reported. 47 The widespread use of macrolides in veterinary medicine has accelerated this resistance trend. Macrolide resistance can also evolve during antibiotic treatment in humans, however it has been infrequently reported. 48 Although trends over time show stable and low rates of macrolide resistance in many countries including Japan, Sweden and Finland 47,49 and in parts of Canada, 50 a rise in macrolide resistance has been reported in human strains in several countries. 33,51,52 Fortunately, the prevalence of erythromycin resistance in C. jejuni has remained low, often well below 12% of isolates. 24,47 In contrast, a higher frequency of resistance is reported in C. coli (up to 70%) which causes <10% of human infections. 24,47 Similarly, in food animals, the prevalence of resistance to erythromycin is generally reported to be higher in C. coli than in C. jejuni. 53 55 In particular, high rates of macrolide resistance have been reported among C. coli isolates from swine, 53 55 possibly as a consequence of the extensive veterinary use of macrolides in pig production. 56 Thus, pigs may represent an important source of infections with erythromycin-resistant C. coli. Globally, multiple antibiotic resistance (MAR; defined as resistance to three or more different classes of antibiotics) is emerging in Campylobacter clinical isolates. 50,52,57 Of particular concern is the emergence of co-resistance to macrolides and fluoroquinolones, 52,57,58 as these are the front-line drugs for treatment of campylobacteriosis. Tetracycline is considered an alternative therapeutic; however, the widespread prevalence of tetracycline resistance, 33,50,52,59 largely attributable to the use of tetracyclines in veterinary medicine for control of infection and growth promotion, 60 makes it a poor choice for treatment. Intravenous aminoglycoside therapy may be considered in more serious cases of infections, such as bacteraemia and other systemic infections. 1 Currently, gentamicin resistance remains negligible; however, the lack of an oral preparation may limit its widespread use. 33 Campylobacter spp. are also generally susceptible to chloramphenicol, clindamycin, nitrofurans and imipenem. 2 Role of active efflux in antibiotic resistance in Campylobacter In 2002, the RND efflux pump CmeABC was described in C. jejuni. 20,21 Insertional mutagenesis of the cmeb gene increased the susceptibility to multiple antibiotics (including fluoroquinolones, erythromycin, tetracycline, chloramphenicol and ampicillin), detergents and dyes, 20,21 defining an active role of the CmeABC multidrug efflux system in the intrinsic resistance of C. jejuni to antibiotics. To date, a number of studies have defined a contributory role of the CmeABC efflux system to acquired fluoroquinolone and macrolide resistance 25 29 and to MAR 26,61,62 in Campylobacter. The CmeABC efflux system is composed of three proteins, CmeB, the energy-dependent efflux pump, CmeC, the outer Page 2 of 7

membrane channel forming protein and CmeA, the adaptor protein. 20 CmeB functions with CmeA and C as an energydependent efflux tripartite complex. Insertional mutagenesis of cmer, an open reading frame coding for a TetR-like regulator, proximal to the cmeabc operon, 21 resulted in overexpression of cmeabc. 63 Moreover, in vitro, recombinant CmeR bound specifically to an inverted repeat sequence located within the promoter region of cmeabc. 63 A single mutation in the inverted repeat region decreased the binding of CmeR in vitro, and resulted in an overexpression of cmeabc. 63 Taken together, these results indicate that CmeR functions as a local repressor for CmeABC. Although a number of other putative efflux pumps, including the RND efflux pump CmeDEF, have been identified by genome analysis, inactivation of the genes encoding these pumps revealed that they do not contribute to the intrinsic or acquired resistance to erythromycin, ciprofloxacin, chloramphenicol or tetracycline. 26,64 However, on the basis of recent evidence that interaction between CmeDEF and CmeABC confers intrinsic resistance to ciprofloxacin and tetracycline in some strains, 65 the possibility of interaction between other efflux pumps in the genesis of resistance cannot be ruled-out and remains to be evaluated. Role of efflux in fluoroquinolone resistance Studies investigating the contribution of efflux to acquired fluoroquinolone resistance in Campylobacter have been somewhat hampered by the unavailability of an efflux inhibitor capable of selectively inhibiting fluoroquinolone efflux. Although the efflux pump inhibitor L-phenylalanine-L-arginine-bnaphthylamine (PAbN) has been shown to increase susceptibility to fluoroquinolones in other bacteria, 66 68 only one study to date has shown a significant decrease in the MICs of fluoroquinolones in Campylobacter in the presence of this inhibitor. 29 We 22,28,69,70 among others, 25,71 73 have refuted this finding by clearly demonstrating a lack of efficacy of PAbN in reversing fluoroquinolone resistance, thereby dismissing its future diagnostic utility in assessing the contribution of efflux to fluoroquinolone resistance in Campylobacter. Nevertheless, by use of a genetic approach involving inactivation of the cmeb gene, direct evidence for the contribution of the CmeABC efflux system to acquired fluoroquinolone resistance has been provided. Compared with wild-type isolates, all cmeb mutants showed a significant decrease in their resistance to fluoroquinolones. 25 28 Furthermore, several studies have shown that the CmeABC pump acts synergistically with gyra mutations to confer fluoroquinolone resistance. 26,27 In contrast to other Gram-negative bacteria where overexpression of efflux pump activity is largely associated with acquired fluoroquinolone resistance, 74 78 fluoroquinolone resistance in Campylobacter does not appear to require overexpression of efflux pumps and may be mediated by single-step point mutations in gyra in the presence of the constitutively expressed CmeABC pump. 26,27 However, based on the findings of Pumbwe et al. 64 that (i) ciprofloxacin-resistant mutants were selected with the same frequency from separate cmeb and cmef knockout strains as from their parent strain and (ii) selected mutant phenotypes from each of the knockout strains showed decreased susceptibility to ciprofloxacin (in the absence of gyra and gyrb mutations), chloramphenicol, detergents and dyes and accumulated less ciprofloxacin and ethidium bromide than their respective parent strains, it would appear that a non-cmeb or -CmeF efflux system may contribute to the ciprofloxacin/multidrug resistance phenotype selected after exposure to a fluoroquinolone. This genetic locus remains to be identified. Role of efflux in macrolide resistance The first report documenting the possible contribution of active efflux to acquired macrolide resistance in Campylobacter was by Mamelli et al. 70 in 2003. They showed that susceptibility to erythromycin and clarithromycin was restored in three of four macrolide-resistant isolates when they were grown in the presence of PAbN. Subsequent studies have highlighted a significant role for the CmeABC efflux system in macrolide resistance. Several studies reported that PAbN 25,28,29 and cmeb inactivation 25,26,28 restored susceptibility in low-level erythromycin-resistant isolates (MICs 4 16 mg/l) carrying no mutated copies of 23S rrna genes. In addition, inactivation of cmeb in four high-level erythromycin-resistant strains (MICs >1024 mg/l) containing the A2075G transitional mutation in the 23S rrna genes decreased the MICs 128- to 512-fold, restoring susceptibility in three strains and returning the remaining strain to a low-level resistance phenotype. 25 cmeb inactivation also restored susceptibility in a high-level erythromycin-resistant isolate (MIC 512 mg/l) with no identified mutations in the 23S rrna genes. 26 In contrast to these findings, PAbN either had no effect, or caused 2- to 8-fold decrease in the MICs of high-level resistant isolates without restoring susceptibility. 25,28,29,79 Despite the limited competitive inhibition of PAbN in high-level resistant isolates, these data provide convincing evidence that the CmeABC efflux system is responsible for low-level erythromycin resistance and that it may act independently or in synergy with 23S rrna mutations to confer high-level erythromycin resistance. The CmeABC pump also contributes to resistance to the macrolides, azithromycin and tylosin 25 and the ketolide telithromycin. 25,28 However, the possibility of the involvement of another PAbN-sensitive efflux system in macrolide resistance cannot be ruled-out, as PAbN was still efficient against erythromycin, clarithromycin and telithromycin in cmeb mutants. 28 Role of efflux in MAR Overexpression of multidrug-resistant efflux pumps mediated by mutations in their regulators is usually associated with acquired resistance to multiple antibiotics. 80 83 In Campylobacter a number of studies have tentatively linked overexpression of cmeb with MAR. 29,62 High levels of expression of CmeB were documented in a number of C. coli MAR isolates from pigs. 29 In addition, Pumbwe et al. 62 reported that MAR was more associated with cmeb overexpression than cmef (9/32 MAR C. jejuni isolates from humans and poultry overexpressed cmeb alone and 3/32 overexpressed both cmeb and cmef). All cmeb overexpressing isolates accumulated less ciprofloxacin than wild-type strains and contained mutations in the CmeR transcriptional repressor protein. However, increased expression of CmeB, as has been demonstrated in a cmer mutant, may not be sufficient alone to generate clinically significant levels of antibiotic resistance. 63 Nevertheless, it may allow bacteria to survive under the pressure of high antibiotic concentrations and promote the emergence of mutants with target gene mutations that are highly resistant to antimicrobials. 82 Direct evidence for the contribution of CmeABC to MAR has been provided by inactivation of cmeb in several MAR-resistant isolates, which resulted in 4 to 256-fold decreases Page 3 of 7

in the MICs of ciprofloxacin, erythromycin and tetracycline. 26 However, overexpression of cmeb was not observed when comparing antibiotic-resistant to antibiotic-susceptible strains. 26 The exact contribution of CmeABC overexpression to MAR needs to be more clearly defined. Interestingly, Lin et al. 20 reported an 8-fold decrease in the MIC of tetracycline in a cmeb mutant that carried the teto gene, suggesting that cmeabc functions synergistically with teto to contribute to acquired tetracycline resistance. This warrants further investigation. A study by Pumbwe et al. 64 postulated the involvement of a non-cmeb or -CmeF efflux pump or reduced uptake in conferring MAR in mutants selected with ciprofloxacin from two efflux knockout strains, cmeb::kan r and cmef::kan r. However, critical evaluation of their data shows that a MAR phenotype was not selected after exposure to ciprofloxacin as only resistance to ciprofloxacin and chloramphenicol was observed. Nonetheless, the possibility of the interaction between different efflux pumps in the genesis of MAR remains to be explored. Role of efflux pumps in Campylobacter in bile resistance and avian gastrointestinal colonization Chickens represent a natural host and major reservoir for C. jejuni. Colonization occurs mainly in the lower intestine where the organism localizes in caecal and cloacal crypts. 84 Normally, colonization of chickens results in a harmless commensal relationship, 85 unlike in mammals where the pathogenesis of campylobacteriosis is associated with destruction of the colonic epithelium and invasion of the lamina propria. 86,87 In order to survive and multiply within the host, Campylobacter and other enterics need to resist multiple stresses in the gastrointestinal tract including the antimicrobial activity of bile and peptides, competition with other flora and attack by the immune system. Bile, which is produced by the liver, is composed primarily of bile salts, bile pigments and to a lesser extent phospholipids and cholesterol. In addition to being essential for the digestion and absorption of fats, bile salts function as antimicrobial agents by disaggregating the lipid bilayers of cellular membranes. 88 In Gram-negative bacteria, bile salts can pass directly across the outer membrane or through porins. 89 Thus, survival of enterics in the intestinal tract has necessitated the evolution of multiple selfdefence mechanisms against the bactericidal effects of bile salts, including use of efflux pumps, producing bile salt hydrolase or modulating synthesis of lipopolysaccharide and porins. 90 92 Of these, efflux of bile salts from the cytoplasm by multidrug efflux pumps is the best-characterized mechanism of bile resistance in Gram-negative bacteria. To date, the only documented mechanism of bile salt resistance in Campylobacter is active efflux. Inactivation of cmeabc significantly decreased the resistance to various bile salts in C. jejuni. 20,30 CmeABC is also essential for growth of Campylobacter in bile-containing media and in animal intestinal tracts as evidenced by the inability of a cmeb null mutant to colonize chickens. 30 More recently, bile salts have been shown to dramatically increase the expression of the cmeabc operon by inhibiting binding of the CmeR repressor protein to the promoter for cmeabc as well as by a CmeR-independent activation pathway. 93 Thus by mediating resistance to bile salts, CmeABC appears to play a significant role in the adaptation of Campylobacter to the intestinal environment in animal hosts. Although the natural function of multidrug efflux pumps is still largely undefined, 94,95 the broad distribution and expression of CmeABC in Campylobacter strains from different sources, 20 its inducibility by bile 93 and its demonstrated role in the export of and resistance to bile salts 20,30 is consistent with a natural role of this system in protecting the microbial cell from the action of these agents in the gut. Of the other identified efflux pumps in Campylobacter, only the contribution of the CmeDEF efflux system to bile resistance has been investigated. However, studies determining the effects of cmef inactivation on susceptibility to bile salts have yielded contradictory results. 64,65 In contrast, cmeb/cmef double mutants showed a significant decrease in resistance to detergents and bile salts compared with their corresponding cmeb mutants, 65 indicating that interaction between both CmeDEF and CmeABC efflux pumps may facilitate the adaptation of Campylobacter to various environments. Furthermore, it appears that CmeABC and CmeDEF interact in maintaining cell viability in Campylobacter and that at least one of them is required for optimal growth, 65 thus defining a role for efflux pumps in Campylobacter physiology. The future potential of efflux pump inhibitors to control Campylobacter infection The increasing recognition of the contribution of multidrug efflux pumps to antibiotic resistance in clinical bacterial isolates, 96 combined with the lack of new antibiotics in development, has resulted in the identification of the efflux machinery as bona fide pharmacological targets in the war against resistance. 97 Over the past decade, many efflux pump inhibitors have been identified by systematic screening of large collections of natural and synthetic compounds and by the testing of known inhibitors of mammalian multidrug efflux pumps and drugs used in human medicine for conditions other than the treatment of infectious diseases. 98 100 Many of these compounds have proved useful for studying the contribution and prevalence of efflux in acquired and intrinsic resistance to multiple antibiotics in bacteria. 97,100 However, to date, no efflux pump inhibitor has been licensed for use in the treatment of bacterial infections in human or veterinary medicine. As knowledge of the structures of efflux pump proteins and their substrate binding domains increase, there will be greater potential to rationally design new inhibitors or increase the efficacy of known ones. The pace at which our understanding of mechanisms of resistance in Campylobacter to important antimicrobial agents has developed has been very impressive. However, our understanding of many of the identified drug transporters in Campylobacter is still limited. The level of synergistic interaction between varying efflux pumps in relation to antibiotic resistance and adaptation to different environmental niches is currently unclear. Nonetheless, the well-documented contribution of the CmeABC efflux pump to antibiotic resistance 25 29 and its critical role in the in vivo adaptation of Campylobacter in chickens 30 suggests that it may be a suitable target for control of Campylobacter infections. Efflux pump inhibitors capable of inhibiting CmeABC could have a potential clinical application in the treatment of antibioticresistant Campylobacter infections by reversing resistance to fluoroquinolones, macrolides and possibly tetracyclines. A further exciting possibility would be the use of inhibitors of CmeABC as Page 4 of 7

feed additives in poultry production systems to prevent/reduce intestinal colonization with Campylobacter. As a significant proportion of all Campylobacter infections have been attributed to the consumption of undercooked poultry or the handling of raw poultry, reduction of colonization in chickens would reduce carcass contamination during slaughter, thereby potentially reducing the incidence of C. jejuni infections in humans. Moreover, the use of efflux inhibitors in poultry production systems could possibly decrease the emergence of antibioticresistant strains that can be transmitted to humans through the food chain. Fluoroquinolone and multidrug resistance in Campylobacter is not clearly associated with overproduction of CmeABC, 26,27 suggesting that CmeABC might have unique regulatory features. To date, this pump has been shown to be controlled by CmeR, which functions as a transcriptional repressor; 63 however, it is unknown whether or not CmeR is controlled by a global regulator. Further elucidation of the regulatory mechanisms modulating the expression of CmeABC together with high-resolution structural information for the regulators may provide opportunities for the design of specific inhibitors that could potentially decrease the transcription of the transport genes. Finally, elucidation of the structures, function and regulation of other efflux pumps present in Campylobacter may in the future identify other novel targets for the therapeutic intervention of Campylobacter infection. Discussion Campylobacter can no longer be described as the unsung bug when it comes to food poisoning, as it is currently heralded as the world leader in foodborne diseases. Infection is largely associated with consumption of undercooked poultry and cross-contamination of other foods with drippings from raw poultry. Increasing prevalence of resistance to macrolides and fluoroquinolones has become a major public health concern as it can compromise treatment in cases of lifethreatening campylobacteriosis. Antibiotic resistance in Campylobacter is mainly a consequence of the use of antimicrobials in food-producing animals. However, even in the absence of antibiotic selective pressure, resistance can persist. The contribution of the CmeABC efflux pump to antimicrobial resistance in Campylobacter together with its role in the in vivo colonization of chickens mark it as a potential future target for the control of Campylobacter infection. The development of rationally designed efflux pump inhibitors that will specifically block its function may potentially reverse clinical antibiotic resistance and decrease the transmission of Campylobacter via the food chain. Other useful strategies, based on the modulation of the avian gut microbial content could also have a significant impact towards reducing the transmission of Campylobacter via the food chain. However, until new control systems are developed, the management of risks associated with the transmission of antibiotic-resistant isolates from food animals to humans should include the following: continuing improvements in food safety, promotion of prudent use of antibiotics in agriculture and veterinary medicine and the implementation and maintenance of global antimicrobial resistance surveillance studies to guide empirical prescribing of antimicrobial agents and to detect newly emerging resistances. Transparency declarations None to declare. References 1. Aarestrup FM, Engberg J. Antimicrobial resistance of thermophilic Campylobacter. Vet Res 2001; 32: 311 21. 2. Allos BM. Campylobacter jejuni Infections: update on emerging issues and trends. Clin Infect Dis 2001; 32: 1201 6. 3. Karmali MA, Penner JL, Fleming PC et al. The serotype and biotype distribution of clinical isolates of Campylobacter jejuni and Campylobacter coli over a three-year period. J Infect Dis 1983; 147: 243 6. 4. Butzler JP. Campylobacter, from obscurity to celebrity. Clin Microbiol Infect 2004; 10: 868 76. 5. Moore JE, Corcoran D, Dooley JS et al. Campylobacter. Vet Res 2005; 36: 351 82. 6. Deming MS, Tauxe RV, Blake PA et al. Campylobacter enteritis at a university: transmission from eating chicken and from cats. Am J Epidemiol 1987; 126: 526 34. 7. Effler P, Ieong MC, Kimura A et al. Sporadic Campylobacter jejuni infections in Hawaii: associations with prior antibiotic use and commercially prepared chicken. J Infect Dis 2001; 183: 1152 5. 8. Hopkins RS, Scott AS. Handling raw chicken as a source for sporadic Campylobacter jejuni infections. J Infect Dis 1983; 148: 770. 9. Evans SJ. Introduction and spread of thermophilic campylobacters in broiler flocks. Vet Rec 1992; 131: 574 6. 10. Stern NJ, Svetoch EA, Eruslanov BV et al. Paenibacillus polymyxa purified bacteriocin to control Campylobacter jejuni in chickens. J Food Prot 2005; 68: 1450 3. 11. Loc Carrillo C, Atterbury RJ, el-shibiny A et al. Bacteriophage therapy to reduce Campylobacter jejuni colonization of broiler chickens. Appl Environ Microbiol 2005; 71: 6554 63. 12. Schoeni JL, Wong AC. Inhibition of Campylobacter jejuni colonization in chicks by defined competitive exclusion bacteria. Appl Environ Microbiol 1994; 60: 1191 7. 13. Travers K, Barza M. Morbidity of infections caused by antimicrobial-resistant bacteria. Clin Infect Dis 2002; 34 Suppl 3: S131 4. 14. Smith KE, Besser JM, Hedberg CW et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992 1998. Investigation Team. N Engl J Med 1999; 340: 1525 32. 15. Helms M, Simonsen J, Olsen KE et al. Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study. J Infect Dis 2005; 191: 1050 5. 16. Helms M, Vastrup P, Gerner-Smidt P et al. Mortality associated with foodborne bacterial gastrointestinal infections. Ugeskr Laeger 2004; 166: 491 3. 17. Engberg J, Neimann J, Nielsen EM et al. Quinolone-resistant Campylobacter infections: risk factors and clinical consequences. Emerg Infect Dis 2004; 10: 1056 63. 18. Taylor DE, Courvalin P. Mechanisms of antibiotic resistance in Campylobacter species. Antimicrob Agents Chemother 1988; 32: 1107 12. 19. Charvalos E, Tselentis Y, Hamzehpour MM et al. Evidence for an efflux pump in multidrug-resistant Campylobacter jejuni. Antimicrob Agents Chemother 1995; 39: 2019 22. 20. Lin J, Michel LO, Zhang Q. CmeABC functions as a multidrug efflux system in Campylobacter jejuni. Antimicrob Agents Chemother 2002; 46: 2124 31. 21. Pumbwe L, Piddock LJ. Identification and molecular characterisation of CmeB, a Campylobacter jejuni multidrug efflux pump. FEMS Microbiol Lett 2002; 206: 185 9. 22. Corcoran D, Quinn T, Cotter L et al. Characterization of a cmeabc operon in a quinolone-resistant Campylobacter coli isolate of Irish origin. Microb Drug Resist 2005; 11: 303 8. Page 5 of 7

23. Payot S, Bolla JM, Corcoran D et al. Mechanisms of fluoroquinolone and macrolide resistance in Campylobacter spp. Microbes Infect 2006; 8: 1967 71. 24. Gibreel A, Taylor DE. Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother 2006; 58: 243 55. 25. Cagliero C, Mouline C, Payot S et al. Involvement of the CmeABC efflux pump in the macrolide resistance of Campylobacter coli. J Antimicrob Chemother 2005; 56: 948 50. 26. Ge B, McDermott PF, White DG et al. Role of efflux pumps and topoisomerase mutations in fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother 2005; 49: 3347 54. 27. Luo N, Sahin O, Lin J et al. In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyra mutations and the function of the CmeABC efflux pump. Antimicrob Agents Chemother 2003; 47: 390 4. 28. Mamelli L, Prouzet-Mauleon V, Pages JM et al. Molecular basis of macrolide resistance in Campylobacter : role of efflux pumps and target mutations. J Antimicrob Chemother 2005; 56: 491 7. 29. Payot S, Avrain L, Magras C et al. Relative contribution of target gene mutation and efflux to fluoroquinolone and erythromycin resistance, in French poultry and pig isolates of Campylobacter coli. Int J Antimicrob Agents 2004; 23: 468 72. 30. Lin J, Sahin O, Michel LO et al. Critical role of multidrug efflux pump CmeABC in bile resistance and in vivo colonization of Campylobacter jejuni. Infect Immun 2003; 71: 4250 9. 31. Angulo FJ, Nargund VN, Chiller TC. Evidence of an association between use of anti-microbial agents in food animals and anti-microbial resistance among bacteria isolated from humans and the human health consequences of such resistance. J Vet Med B Infect Dis Vet Public Health 2004; 51: 374 9. 32. Fields PI, Swerdlow DL. Campylobacter jejuni. Clin Lab Med 1999; 19: 489 504, v. 33. Moore JE, Barton MD, Blair IS et al. The epidemiology of antibiotic resistance in Campylobacter. Microbes Infect 2006; 8: 1955 66. 34. Li CC, Chiu CH, Wu JL et al. Antimicrobial susceptibilities of Campylobacter jejuni and coli by using E-test in Taiwan. Scand J Infect Dis 1998; 30: 39 42. 35. Murphy GS Jr, Echeverria P, Jackson LR et al. Ciprofloxacinand azithromycin-resistant Campylobacter causing traveler s diarrhea in U.S. troops deployed to Thailand in 1994. Clin Infect Dis 1996; 22: 868 9. 36. Prats G, Mirelis B, Llovet T et al. Antibiotic resistance trends in enteropathogenic bacteria isolated in 1985 1987 and 1995 1998 in Barcelona. Antimicrob Agents Chemother 2000; 44: 1140 5. 37. Lucey B, Cryan B, O Halloran F et al. Trends in antimicrobial susceptibility among isolates of Campylobacter species in Ireland and the emergence of resistance to ciprofloxacin. Vet Rec 2002; 151: 317 20. 38. Luber P, Wagner J, Hahn H et al. Antimicrobial resistance in Campylobacter jejuni and Campylobacter coli strains isolated in 1991 and 2001 2002 from poultry and humans in Berlin, Germany. Antimicrob Agents Chemother 2003; 47: 3825 30. 39. Gaudreau C, Gilbert H. Antimicrobial resistance of clinical strains of Campylobacter jejuni subsp. jejuni isolated from 1985 to 1997 in Quebec, Canada. Antimicrob Agents Chemother 1998; 42: 2106 8. 40. Talsma E, Goettsch WG, Nieste HL et al. Resistance in Campylobacter species: increased resistance to fluoroquinolones and seasonal variation. Clin Infect Dis 1999; 29: 845 8. 41. Endtz HP, Ruijs GJ, van Klingeren B et al. Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother 1991; 27: 199 208. 42. Gaunt PN, Piddock LJ. Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. J Antimicrob Chemother 1996; 37: 747 57. 43. Humphrey TJ, Jorgensen F, Frost JA et al. Prevalence and subtypes of ciprofloxacin-resistant Campylobacter spp. in commercial poultry flocks before, during, and after treatment with fluoroquinolones. Antimicrob Agents Chemother 2005; 49: 690 8. 44. Unicomb LE, Ferguson J, Stafford RJ et al. Low-level fluoroquinolone resistance among Campylobacter jejuni isolates in Australia. Clin Infect Dis 2006; 42: 1368 74. 45. Price LB, Johnson E, Vailes R et al. Fluoroquinolone-resistant Campylobacter isolates from conventional and antibiotic-free chicken products. Environ Health Perspect 2005; 113: 557 60. 46. Luo N, Pereira S, Sahin O et al. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc Natl Acad Sci USA 2005; 102: 541 6. 47. Engberg J, Aarestrup FM, Taylor DE et al. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli : resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001; 7: 24 34. 48. Funke G, Baumann R, Penner JL et al. Development of resistance to macrolide antibiotics in an AIDS patient treated with clarithromycin for Campylobacter jejuni diarrhea. Eur J Clin Microbiol Infect Dis 1994; 13: 612 5. 49. Osterlund A, Hermann M, Kahlmeter G. Antibiotic resistance among Campylobacter jejuni/coli strains acquired in Sweden and abroad: a longitudinal study. Scand J Infect Dis 2003; 35: 478 81. 50. Gibreel A, Tracz DM, Nonaka L et al. Incidence of antibiotic resistance in Campylobacter jejuni isolated in Alberta, Canada, from 1999 to 2002, with special reference to tet(o)-mediated tetracycline resistance. Antimicrob Agents Chemother 2004; 48: 3442 50. 51. Rao D, Rao JR, Crothers E et al. Increased erythromycin resistance in clinical Campylobacter in Northern Ireland an update. J Antimicrob Chemother 2005; 55: 395 6. 52. Gaudreau C, Gilbert H. Antimicrobial resistance of Campylobacter jejuni subsp. jejuni strains isolated from humans in 1998 to 2001 in Montreal, Canada. Antimicrob Agents Chemother 2003; 47: 2027 9. 53. Bywater R, Deluyker H, Deroover E et al. A European survey of antimicrobial susceptibility among zoonotic and commensal bacteria isolated from food-producing animals. J Antimicrob Chemother 2004; 54: 744 54. 54. Aarestrup FM, Nielsen EM, Madsen M et al. Antimicrobial susceptibility patterns of thermophilic Campylobacter spp. from humans, pigs, cattle, and broilers in Denmark. Antimicrob Agents Chemother 1997; 41: 2244 50. 55. Saenz Y, Zarazaga M, Lantero M et al. Antibiotic resistance in Campylobacter strains isolated from animals, foods, and humans in Spain in 1997 1998. Antimicrob Agents Chemother 2000; 44: 267 71. 56. Moore JE, Madden RH, Kerr JR et al. Erythromycin-resistant thermophilic Campylobacter species isolated from pigs. Vet Rec 1996; 138: 306 7. 57. Hakanen AJ, Lehtopolku M, Siitonen A et al. Multidrug resistance in Campylobacter jejuni strains collected from Finnish patients during 1995 2000. J Antimicrob Chemother 2003; 52: 1035 9. 58. Hoge CW, Gambel JM, Srijan A et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26: 341 5. 59. Pratt A, Korolik V. Tetracycline resistance of Australian Campylobacter jejuni and Campylobacter coli isolates. J Antimicrob Chemother 2005; 55: 452 60. 60. McEwen SA, Fedorka-Cray PJ. Antimicrobial use and resistance in animals. Clin Infect Dis 2002; 34 Suppl 3: S93 106. 61. Payot S, Dridi S, Laroche M et al. Prevalence and antimicrobial resistance of Campylobacter coli isolated from fattening pigs in France. Vet Microbiol 2004; 101: 91 9. Page 6 of 7

62. Pumbwe L, Randall LP, Woodward MJ et al. Expression of the efflux pump genes cmeb, cmef and the porin gene pora in multipleantibiotic-resistant Campylobacter jejuni. J Antimicrob Chemother 2004; 54: 341 7. 63. Lin J, Akiba M, Sahin O et al. CmeR functions as a transcriptional repressor for the multidrug efflux pump CmeABC in Campylobacter jejuni. Antimicrob Agents Chemother 2005; 49: 1067 75. 64. Pumbwe L, Randall LP, Woodward MJ et al. Evidence for multiple-antibiotic resistance in Campylobacter jejuni not mediated by CmeB or CmeF. Antimicrob Agents Chemother 2005; 49: 1289 93. 65. Akiba M, Lin J, Barton YW et al. Interaction of CmeABC and CmeDEF in conferring antimicrobial resistance and maintaining cell viability in Campylobacter jejuni. J Antimicrob Chemother 2006; 57: 52 60. 66. Mallea M, Chevalier J, Eyraud A et al. Inhibitors of antibiotic efflux pump in resistant Enterobacter aerogenes strains. Biochem Biophys Res Commun 2002; 293: 1370 3. 67. Lomovskaya O, Warren MS, Lee A et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa : novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45: 105 16. 68. Baucheron S, Imberechts H, Chaslus-Dancla E et al. The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in Salmonella enterica serovar typhimurium phage type DT204. Microb Drug Resist 2002; 8: 281 9. 69. Corcoran D, Quinn T, Cotter L et al. Relative contribution of target gene mutation and efflux to varying quinolone resistance in Irish Campylobacter isolates. FEMS Microbiol Lett 2005; 253: 39 46. 70. Mamelli L, Amoros JP, Pages JM et al. A phenylalanine-arginine beta-naphthylamide sensitive multidrug efflux pump involved in intrinsic and acquired resistance of Campylobacter to macrolides. Int J Antimicrob Agents 2003; 22: 237 41. 71. Payot S, Cloeckaert A, Chaslus-Dancla E. Selection and characterization of fluoroquinolone-resistant mutants of Campylobacter jejuni using enrofloxacin. Microb Drug Resist 2002; 8: 335 43. 72. Laatu M, Rautelin H, Hanninen ML. Susceptibility of Campylobacter hyointestinalis subsp. hyointestinalis to antimicrobial agents and characterization of quinolone-resistant strains. J Antimicrob Chemother 2005; 55: 182 7. 73. Ruiz J, Moreno A, Jimenez de Anta MT et al. A double mutation in the gyra gene is necessary to produce high levels of resistance to moxifloxacin in Campylobacter spp. clinical isolates. Int J Antimicrob Agents 2005; 25: 542 5. 74. Cebrian L, Rodriguez JC, Escribano I et al. Characterization of Salmonella spp. mutants with reduced fluoroquinolone susceptibility: importance of efflux pump mechanisms. Chemotherapy 2005; 51: 40 3. 75. Chu C, Su LH, Chu CH et al. Resistance to fluoroquinolones linked to gyra and parc mutations and overexpression of acrab efflux pump in Salmonella enterica serotype Choleraesuis. Microb Drug Resist 2005; 11: 248 53. 76. Niga T, Ito H, Oyamada Y et al. Cooperation between alteration of DNA gyrase genes and over-expression of MexB and MexX confers high-level fluoroquinolone resistance in Pseudomonas aeruginosa strains isolated from a patient who received a liver transplant followed by treatment with fluoroquinolones. Microbiol Immunol 2005; 49: 443 6. 77. Hopkins KL, Davies RH, Threlfall EJ. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents 2005; 25: 358 73. 78. Poole K. Efflux-mediated resistance to fluoroquinolones in Gram-positive bacteria and the mycobacteria. Antimicrob Agents Chemother 2000; 44: 2595 9. 79. Corcoran D, Quinn T, Cotter L et al. An investigation of the molecular mechanisms contributing to high-level erythromycin resistance in Campylobacter. Int J Antimicrob Agents 2006; 27: 40 5. 80. Wang H, Dzink-Fox JL, Chen M et al. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrr mutations. Antimicrob Agents Chemother 2001; 45: 1515 21. 81. Adewoye L, Sutherland A, Srikumar R et al. The mexr repressor of the mexab-oprm multidrug efflux operon in Pseudomonas aeruginosa: characterization of mutations compromising activity. J Bacteriol 2002; 184: 4308 12. 82. Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 2003; 51: 9 11. 83. Olliver A, Valle M, Chaslus-Dancla E et al. Role of an acrr mutation in multidrug resistance of in vitro-selected fluoroquinoloneresistant mutants of Salmonella enterica serovar Typhimurium. FEMS Microbiol Lett 2004; 238: 267 72. 84. Beery JT, Hugdahl MB, Doyle MP. Colonization of gastrointestinal tracts of chicks by Campylobacter jejuni. Appl Environ Microbiol 1988; 54: 2365 70. 85. Shane SM. Campylobacter infection of commercial poultry. Rev Sci Tech 2000; 19: 376 95. 86. Kopecko DJ, Hu L, Zaal KJ. Campylobacter jejuni microtubuledependent invasion. Trends Microbiol 2001; 9: 389 96. 87. Russell RG, O Donnoghue M, Blake DC Jr et al. Early colonic damage and invasion of Campylobacter jejuni in experimentally challenged infant Macaca mulatta. J Infect Dis 1993; 168: 210 5. 88. Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev 2005; 29: 625 51. 89. Thanassi DG, Cheng LW, Nikaido H. Active efflux of bile salts by Escherichia coli. J Bacteriol 1997; 179: 2512 8. 90. De Boever P, Wouters R, Verschaeve L et al. Protective effect of the bile salt hydrolase-active Lactobacillus reuteri against bile salt cytotoxicity. Appl Microbiol Biotechnol 2000; 53: 709 14. 91. Gunn JS. Mechanisms of bacterial resistance and response to bile. Microbes Infect 2000; 2: 907 13. 92. Lin J, Huang S, Zhang Q. Outer membrane proteins: key players for bacterial adaptation in host niches. Microbes Infect 2002; 4: 325 31. 93. Lin J, Cagliero C, Guo B et al. Bile salts modulate expression of the CmeABC multidrug efflux pump in Campylobacter jejuni. J Bacteriol 2005; 187: 7417 24. 94. Poole K, Russell AD, Lambert PA. Mechanisms of antimicrobial resistance: opportunities for new targeted therapies. Adv Drug Deliv Rev 2005; 57: 1443 5. 95. Neyfakh AA. Natural functions of bacterial multidrug transporters. Trends Microbiol 1997; 5: 309 13. 96. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006; 19: 382 402. 97. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic a vision for applied use. Biochem Pharmacol 2006; 71: 910 8. 98. Lynch AS. Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention? An industry view. Biochem Pharmacol 2006; 71: 949 56. 99. Marquez B. Bacterial efflux systems and efflux pumps inhibitors. Biochimie 2005; 87: 1137 47. 100. Pages JM, Masi M, Barbe J. Inhibitors of efflux pumps in Gramnegative bacteria. Trends Mol Med 2005; 11: 382 9. Page 7 of 7